1. Engineering a "detect and destroy" skin probiotic to combat methicillin-resistant Staphylococcus aureus.
- Author
-
Guan C, Larson PJ, Fleming E, Tikhonov AP, Mootien S, Grossman TH, Golino C, and Oh J
- Subjects
- Humans, Staphylococcus aureus physiology, Anti-Bacterial Agents therapeutic use, Virulence, Microbial Sensitivity Tests, Methicillin-Resistant Staphylococcus aureus, Probiotics therapeutic use, Staphylococcal Infections drug therapy
- Abstract
The prevalence and virulence of pathogens such as methicillin-resistant Staphylococcus (S.) aureus (MRSA), which can cause recurrent skin infections, are of significant clinical concern. Prolonged antibiotic exposure to treat or decolonize S. aureus contributes to development of antibiotic resistance, as well as depletion of the microbiome, and its numerous beneficial functions. We hypothesized an engineered skin probiotic with the ability to selectively deliver antimicrobials only in the presence of the target organism could provide local bioremediation of pathogen colonization. We constructed a biosensing S. epidermidis capable of detecting the presence of S. aureus quorum sensing autoinducer peptide and producing lysostaphin in response. Here, we demonstrate in vitro activity of this biosensor and present and discuss challenges to deployment of this and other engineered topical skin probiotics., Competing Interests: JO is on the scientific advisory board of Azitra, Inc., Dermbiont, Inc., and ELSI Skin Health, Inc. AT, SM are employed by Azitra, Inc. TG is formerly employed by Azitra, Inc. This does not alter our adherence to LOS ONE policies on sharing data and materials., (Copyright: © 2022 Guan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2022
- Full Text
- View/download PDF